menu search

EPIX / ESSA Pharma: One Asset, One Program Company With Little Data

ESSA Pharma: One Asset, One Program Company With Little Data
EPIX is targeting prostate cancer with its lead and only asset EPI-7386. While there's some rationale to the molecule's science, there's not a lot of convincing data yet. Read More
Posted: Feb 6 2023, 08:28
Author Name: Seeking Alpha
Views: 102460

EPIX News  

ESSA Pharma: One Asset, One Program Company With Little Data

By Seeking Alpha
February 6, 2023

ESSA Pharma: One Asset, One Program Company With Little Data

EPIX is targeting prostate cancer with its lead and only asset EPI-7386. While there's some rationale to the molecule's science, there's not a lot of more_horizontal

ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancer

By Seeking Alpha
November 15, 2022

ESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate Cancer

The stock has pulled back from the 2x pop after the recent data of EPI-7386+Xtandi in post-chemotherapy metastatic castration-resistant prostate cance more_horizontal


Search within

Pages Search Results: